Alpha 2.0
Login Register
» Articles » PMID: 34686554

Observational Study of the Relative Efficacy of Insulin-glucose Treatment for Hyperkalaemia in Patients with Liver Cirrhosis

Overview
Journal BMJ Open
Specialty General Medicine
Date 2021 Oct 23
PMID 34686554
Authors
Andy K H Lim
Ljiljana Crnobrnja
Manogna Metlapalli
Cathy Jiang
Rene S H Wang
Jeanette H Pham
Joshua H Abasszade
Affiliations
Soon will be listed here.
Abstract

Objectives: To determine if liver cirrhosis is associated with reduced efficacy of insulin-glucose treatment in moderate to severe hyperkalaemia.

Design: Retrospective, cohort study.

Setting: Two secondary and one tertiary care hospital at a large metropolitan healthcare network in Melbourne, Australia.

Participants: This study included 463 adults with a mean age of 68.7±15.8 years, comprising 79 patients with cirrhosis and 384 without cirrhosis as controls, who received standard insulin-glucose treatment for a serum potassium ≥6.0 mmol/L from October 2016 to March 2020. Patients were excluded if they received an insulin infusion, or if there was inadequate follow-up data for at least 6 hours after IDT due to death, lost to follow-up or inadequate biochemistry monitoring. The mean Model for End-stage Liver Disease score in patients with cirrhosis was 22.2±7.5, and the distribution of the Child-Pugh score for cirrhosis was: class A (24%), class B (46%), class C (30%).

Outcome Measures: The primary outcome was the degree of potassium lowering and the secondary outcome was the proportion of patients who achieved normokalaemia, within 6 hours of treatment.

Results: The mean pretreatment potassium for the cohort was 6.57±0.52 mmol/L. After insulin-glucose treatment, mean potassium lowering was 0.84±0.58 mmol/L in patients with cirrhosis compared with 1.33±0.75 mmol/L for controls (p<0.001). The proportion of patients achieving normokalaemia was 33% for patients with cirrhosis, compared with 53% for controls (p=0.001). By multivariable regression, on average, liver cirrhosis was associated with a reduced potassium lowering effect of 0.42 mmol/L (95% CI 0.22 to 0.63 mmol/L, p<0.001) from insulin-glucose treatment, after adjusting for age, serum creatinine, cancer, pretreatment potassium level, β-blocker use and cotreatments (sodium polystyrene sulfonate, salbutamol, sodium bicarbonate).

Conclusions: Our observational data suggest reduced efficacy of insulin-glucose treatment for hyperkalaemia in patients with cirrhosis.

References
1.
Goswami A, Bhargava N, Dadhich S, Kulamarva G . Insulin resistance in euglycemic cirrhosis. Ann Gastroenterol. 2014; 27(3):237-243. PMC: 4073020. View
2.
Siew E, Ikizler T, Matheny M, Shi Y, Schildcrout J, Danciu I . Estimating baseline kidney function in hospitalized patients with impaired kidney function. Clin J Am Soc Nephrol. 2012; 7(5):712-9. PMC: 3338282. DOI: 10.2215/CJN.10821011. View
3.
Varallo F, Trombotto V, Lucchetta R, Mastroianni P . Efficacy and safety of the pharmacotherapy used in the management of hyperkalemia: a systematic review. Pharm Pract (Granada). 2019; 17(1):1361. PMC: 6463413. DOI: 10.18549/PharmPract.2019.1.1361. View
4.
Iannello S, Milazzo P, Belfiore F . Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007; 8(3):231-51. DOI: 10.1111/j.1467-789X.2006.00276.x. View
5.
Shan W, Chen B, Zhu S, Jiang L, Zhou Y . Effects of GLUT4 expression on insulin resistance in patients with advanced liver cirrhosis. J Zhejiang Univ Sci B. 2011; 12(8):677-82. PMC: 3150722. DOI: 10.1631/jzus.B1100001. View